EGFR and breast carcinoma: The extract moderately inhibited α-glucosidase (IC50 = 110 ± 4.25 μg/mL), suggesting that it has antidiabetic activity, and downregulated Epidermal Growth Factor Receptor (EGFR) expression in a human breast cancer cell line (MCF7), suggesting that it has anticancer effects [27].